{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao Q"],"funding":["Ministry of Science and Technology of the People's Republic of China (MOST)","Guangdong Provincial Key Laboratory of Construction Foundation ()","Guangzhou Municipal Science and Technology Bureau (GZST)","Guangdong Special Support Plan ()","Sun Yat-sen University (SYSU)"],"pagination":["3886-3896"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434392"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(18)"],"pubmed_abstract":["Purpose
This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)-T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV-hepatocellular carcinoma after liver transplantation.Patients and methods
In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV-TCR-T cells (mRNA-HBV-TCR-T cells) and (ii) one to three infusions of lentiviral-transduced HBV-TCR-T cells (lenti-HBV-TCR-T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor effic"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["HBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation."],"pmcid":["PMC12434392"],"funding_grant_id":["R07015","2023YFF1501200","2020B1212060026","2024A04J6388","82470687","82404650","R70004","2024B03J1235","Y-2023-756","2023YFF1501202","82270686"],"pubmed_authors":["Li J","Koh S","Tan H","Guo Z","Huang J","Qin M","Wai LE","Dan J","Liu Z","Zhao Q","Wang T","He X","Luo W","Wong RWJ"],"additional_accession":[]},"is_claimable":false,"name":"HBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation.","description":"Purpose
This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)-T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV-hepatocellular carcinoma after liver transplantation.Patients and methods
In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV-TCR-T cells (mRNA-HBV-TCR-T cells) and (ii) one to three infusions of lentiviral-transduced HBV-TCR-T cells (lenti-HBV-TCR-T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor effic","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-02T05:27:32.858Z","creation":"2026-04-14T03:14:17.377Z"},"accession":"S-EPMC12434392","cross_references":{"pubmed":["40705079"],"doi":["10.1158/1078-0432.CCR-25-1245"]}}